CLINICAL TRIALS PROFILE FOR ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

All Clinical Trials for estrogens, conjugated; medroxyprogesterone acetate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.

Clinical Trial Conditions for estrogens, conjugated; medroxyprogesterone acetate

Condition Name

Condition Name for estrogens, conjugated; medroxyprogesterone acetate
Intervention	Trials
Osteoporosis	2
Postmenopause	2
Coronary Disease	1

Condition MeSH

Condition MeSH for estrogens, conjugated; medroxyprogesterone acetate
Intervention	Trials
Osteoporosis	2
Heart Diseases	1
Lupus Erythematosus, Systemic	1

Clinical Trial Locations for estrogens, conjugated; medroxyprogesterone acetate

Trials by Country

Trials by Country for estrogens, conjugated; medroxyprogesterone acetate
Location	Trials
Taiwan	2
Brazil	1
Mexico	1
Netherlands	1
Italy	1

Clinical Trial Progress for estrogens, conjugated; medroxyprogesterone acetate

Clinical Trial Phase

Clinical Trial Phase for estrogens, conjugated; medroxyprogesterone acetate
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	2
N/A	1

Clinical Trial Status

Clinical Trial Status for estrogens, conjugated; medroxyprogesterone acetate
Clinical Trial Phase	Trials
Completed	4
Active, not recruiting	1
Recruiting	1

Clinical Trial Sponsors for estrogens, conjugated; medroxyprogesterone acetate

Sponsor Name

Sponsor Name for estrogens, conjugated; medroxyprogesterone acetate
Sponsor	Trials
National Institute on Aging (NIA)	1
National Heart, Lung, and Blood Institute (NHLBI)	1
Organon	1

Sponsor Type

Sponsor Type for estrogens, conjugated; medroxyprogesterone acetate
Sponsor	Trials
Other	5
NIH	5
Industry	1